Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases

Journal of Autoimmunity

Volumn 26, Issue 3, 2006, Pages 165-171

  Goules, Andreas ^a   Tzioufas, Athanasios G ^a   Manousakis, Menelaos N ^a   Kirou, Kyriakos A ^b   Crow, Mary K ^b   Routsias, John G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Autoimmunity; sCD40L; Sj gren's syndrome; Soluble CD40 ligand; Systemic lupus erythematosus

Indexed keywords

CD40 LIGAND;

ANTIGEN DETECTION; ARTICLE; AUTOIMMUNE DISEASE; BLOOD LEVEL; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RHEUMATOID ARTHRITIS; SALIVA ANALYSIS; SJOEGREN SYNDROME; SYSTEMIC DISEASE; URINALYSIS;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CD40 LIGAND; CRYOGLOBULINEMIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULONEPHRITIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PERIPHERAL NERVOUS SYSTEM DISEASES; RHEUMATOID FACTOR; SALIVA; SJOGREN'S SYNDROME;

EID: 33646694553     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2006.02.002     Document Type: Article

References (52)

1. Grewal I.S., and Flavell R.A. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 153 (1996) 85-106
2. Grewal I.S., and Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16 (1998) 111-135
3. Grewal I.S., and Flavell R.A. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today 17 (1996) 410-414
4. Datta S.K., and Kalled S.L. CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum 40 (1997) 1735-1745
5. Otterdal K., Pedersen T.M., and Solum N.O. Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase. Thromb Res 114 (2004) 167-177
6. Koshy M., Berger D., and Crow M.K. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98 (1996) 826-837
7. Wang C.R., and Liu M.F. Regulation of CCR5 expression and MIP-1alpha production in CD4+ T cells from patients with rheumatoid arthritis. Clin Exp Immunol 132 (2003) 371-378
8. Grewal I.S., Foellmer H.G., Grewal K.D., Xu J., Hardardottir F., Baron J.L., et al. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 273 (1996) 1864-1867
9. Filion L.G., Matusevicius D., Graziani-Bowering G.M., Kumar A., and Freedman M.S. Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis. Clin Immunol 106 (2003) 127-138
10. Ludwiczek O., Kaser A., and Tilg H. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int J Colorectal Dis 18 (2003) 142-147
11. Toubi E., Adir-Shani A., Kessel A., Shmuel Z., Sabo E., and Hacham H. Immune aberrations in B and T lymphocytes derived from chronic urticaria patients. J Clin Immunol 20 (2000) 371-378
12. Lederer S.R., Friedrich N., Gruber R., Landgraf R., Toepfer M., and Sitter T. Reduced CD40L expression on ex vivo activated CD4+ T lymphocytes from patients with excellent renal allograft function measured with a rapid whole blood flow cytometry procedure. Int Arch Allergy Immunol 133 (2004) 276-284
13. Vakkalanka R.K., Woo C., Kirou K.A., Koshy M., Berger D., and Crow M.K. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 42 (1999) 871-881
14. Kato K., Santana-Sahagun E., Rassenti L.Z., Weisman M.H., Tamura N., Kobayashi S., et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 104 (1999) 947-955
15. Desai-Mehta A., Lu L., Ramsey-Goldman R., and Datta S.K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97 (1996) 2063-2073
16. Devi B.S., Van Noordin S., Krausz T., and Davies K.A. Peripheral blood lymphocytes in SLE-hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J Autoimmun 11 (1998) 471-475
17. Bijl M., Horst G., Limburg P.C., and Kallenberg C.G. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 60 (2001) 523-526
18. Harigai M., Hara M., Fukasawa C., Nakazawa S., Kawaguchi Y., Kamatani N., et al. Responsiveness of peripheral blood B cells to recombinant CD40 ligand in patients with systemic lupus erythematosus. Lupus 8 (1999) 227-233
19. Nagafuchi H., Shimoyama Y., Kashiwakura J., Takeno M., Sakane T., and Suzuki N. Preferential expression of B7.2 (CD86), but not B7.1 (CD80), on B cells induced by CD40/CD40L interaction is essential for anti-DNA autoantibody production in patients with systemic lupus erythematosus. Clin Exp Rheumatol 21 (2003) 71-77
20. Katsiari C.G., Liossis S.N., Souliotis V.L., Dimopoulos A.M., Manoussakis M.N., and Sfikakis P.P. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol 103 (2002) 54-62
21. Mohan C., Shi Y., Laman J.D., and Datta S.K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 154 (1995) 1470-1480
22. Peng S.L., McNiff J.M., Madaio M.P., Ma J., Owen M.J., Flavell R.A., et al. Alpha beta T cell regulation and CD40 ligand dependence in murine systemic autoimmunity. J Immunol 158 (1997) 2464-2470
23. Blossom S., Chu E.B., Weigle W.O., and Gilbert K.M. CD40 ligand expressed on B cells in the BXSB mouse model of systemic lupus erythematosus. J Immunol 159 (1997) 4580-4586
24. Santos-Argumedo L., Alvarez-Maya I., Romero-Ramirez H., and Flores-Romo L. Enforced and prolonged CD40 ligand expression triggers autoantibody production in vivo. Eur J Immunol 31 (2001) 3484-3492
25. Higuchi T., Aiba Y., Nomura T., Matsuda J., Mochida K., Suzuki M., et al. Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J Immunol 168 (2002) 9-12
26. Daikh D.I., Finck B.K., Linsley P.S., Hollenbaugh D., and Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 159 (1997) 3104-3108
27. Kalled S.L., Cutler A.H., Datta S.K., and Thomas D.W. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 160 (1998) 2158-2165
28. Early G.S., Zhao W., and Burns C.M. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 157 (1996) 3159-3164
29. Quezada S.A., Eckert M., Adeyi O.A., Schned A.R., Noelle R.J., and Burns C.M. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum 48 (2003) 2541-2554
30. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48 (2003) 719-727
31. Nakamura H., Kawakami A., Tominaga M., Migita K., Kawabe Y., Nakamura T., et al. Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjögren's syndrome. Lab Invest 79 (1999) 261-269
32. Ping L., Ogawa N., and Sugai S. Novel role of CD40 in Fas-dependent apoptosis of cultured salivary epithelial cells from patients with Sjögren's syndrome. Arthritis Rheum 52 (2005) 573-581
33. Brignole F., Pisella PJ., Goldschild M., De Saint Jean M., Goguel A., and Baudouin C. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci 41 (2000) 1356-1363
34. Ohlsson M., Szodoray P., Loro L.L., Johannessen A.C., and Jonsson R. CD40, CD154, Bax and Bcl-2 expression in Sjögren's syndrome salivary glands: a putative anti-apoptotic role during its effector phases. Scand J Immunol 56 (2002) 561-571
35. Dimitriou I.D., Kapsogeorgou E.K., Moutsopoulos H.M., and Manoussakis M.N. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren's syndrome patients indicating their intrinsic activation. Clin Exp Immunol 127 (2002) 386-392
36. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
37. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
38. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61 (2002) 554-558
39. Tamura N., Kobayashi S., Kato K., Bando H., Haruta K., Oyanagi M., et al. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol 28 (2001) 2583-2590
40. Varo N., de Lemos J.A., Libby P., Morrow D.A., Murohy S.A., Nuzzo R., et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
41. Aggarwal A., Schneider D.J., Terrien E.F., Sobel B.E., and Dauerman H.L. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol 93 (2004) 6-9
42. Komura K., Sato S., Hasegawa M., Fujimoto M., and Takehara K. Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 31 (2004) 514-519
43. Jinnin M., Ihn H., Yazawa N., Asano Y., Yamane K., and Tamaki K. Elevated circulating soluble CD40 ligand in patients with mixed connective tissue disease. Clin Rheumatol 22 (2003) 37-39
44. Nagahama M., Nomura S., Kanazawa S., Ozaki Y., Kagawa H., and Fukuhara S. Significance of chemokines and soluble CD40 ligand in patients with autoimmune thrombocytopenic purpura. Eur J Haematol 69 (2002) 303-308
45. Kuroiwa T., Schlimgen R., Illei G.G., McInnes I.B., and Boumpas D.T. Distinct T cell/renal tubular epithelial cell interactions define differential chemokine production: implications for tubulointerstitial injury in chronic glomerulonephritides. J Immunol 164 (2000) 3323-3329
46. Yellin M.J., D'Agati V., Parkinson G., Han A.S., Szema A., Bazum D., et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 40 (1997) 124-134
47. Camici M. Renal glomerular permselectivity and vascular endothelium. Biomed Pharmacother 59 (2005) 30-37
48. Tzioufas A. Sjögren's syndrome. In: Hochberg M. (Ed). Rheumatology (2003), Elsevier, St. Louis 1431
49. Manoussakis M.N., and Moutsopoulos H.M. Sjögren's syndrome: autoimmune epithelitis. Baillieres Best Pract Res Clin Rheumatol 14 (2000) 73-95
50. Goules A., Masouridi S., Tzioufas A.G., Ioannidis J.P., Skopouli F.N., and Moutsopoulos H.M. Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore) 79 (2000) 241-249
51. Tzioufas A.G., Boumba D.S., Skopouli F.N., and Moutsopoulos H.M. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 39 (1996) 767-772
52. Tzioufas A.G. B-cell lymphoproliferation in primary Sjögren's syndrome. Clin Exp Rheumatol 14 Suppl. 14 (1996) S65-S70